How to take mabelantuzumab and what is the correct dosage?

Belantuzumab (trade name: Blenrep) is an innovative treatment for relapsed or refractory multiple myeloma . It is particularly suitable for adult patients who have received at least four treatments (including anti-CD38 monoclonal antibodies, proteasome inhibitors and immunomodulators) but whose disease has not been controlled. Before using belantuzumab, patients must undergo a comprehensive eye examination to ensure eye health, as the drug has the potential to cause adverse corneal reactions. Eye exams should also be performed regularly during treatment to monitor any potential eye changes.

Regarding how you take berantuzumab, it’s important to be clear that it is an intravenous infusion, not an oral formulation. According to the instructions, the recommended dose of belantuzumab is 2.5 mg/kg, which should be infused intravenously every 3 weeks, with each infusion lasting approximately 30 minutes. This dose and dosing frequency are determined based on clinical trial data and patient tolerance, aiming to achieve the best therapeutic effect. It is important that this medication is administered slowly to ensure patient safety and comfort.

However, if the patient experiences adverse reactions during use, medical staff may adjust the dose based on the specific situation. For patients who experience corneal adverse reactions or other unacceptable toxicity, the recommended dose may be reduced to 1.9 mg/kg intravenously every 3 weeks. If the patient is unable to tolerate this dose, belantuzumab should be discontinued.

Dose adjustments for corneal adverse reactions should be based on corneal examination results and changes in best corrected visual acuity (BCVA). Healthcare providers will determine the recommended dosage adjustment for belantuzumab based on the worst findings in the most affected eye.

In conclusion, belantuzumab is an effective treatment for relapsed or refractory multiple myeloma, but its use must be under the supervision of a medical institution. Patients should follow the instructions of medical staff, receive intravenous infusions on time, and pay attention to monitoring of eye health and adverse reactions. Through appropriate dosage adjustment and eye care, the therapeutic effect of belantuzumab can be maximized while ensuring patient safety and comfort.

Reference materials:https://www.drugs.com/search.php?searchterm=Blenrep&sources%5B%5D=professional